China Traditional Chinese Medicine Holdings Co. Limited

China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of Chinese medicine and pharmaceutical products in the People's Republic of China. The company offers granules, finished drugs, decoction pieces, and healthcare products. It is also involved in the plantation and management of Chinese medicinal herbs; manufacturing of traditional Chinese medicines (TCM); trading of pharmaceutical products; provision of TCM marketing, advertising, and consulting services; and retail of pharmaceuticals and decoction products. The company also provides property leasing services. It sells its products to hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in July 2016. China Traditional China Traditional Chinese Medicine Holdings Co. Limited was founded in 1573 and is headquartered in Wan Chai, Hong Kong.

China Traditional Chinese Medicine Holdings Co. Limited trades as CHIZF on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $14.36B of revenue and -$333.24M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

China Traditional Chinese Medicine Holdings Co. Limited can be compared against peers such as CStone Pharmaceuticals, Evotec SE, Genetic Technologies Limited, Kissei Pharmaceutical Co., Ltd., SSY Group Limited, Nippon Shinyaku Co., Ltd..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $1.10B, beta of 0.71, and return on equity of -1.6%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CHIZF currently shows total debt of $2.49B and beta of 0.71. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.china-tcm.com.cn

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.